SWX, the Swiss stock exchange, has closed its investigation into Jomed, the troubled medical technology company, with a reprimand for breaching listing rules by wilfully overstating its 2001 revenues through false accounting.

The exchange launched an investigation into the company after Jomed's own internal inquiry in January uncovered "improper bookings on a massive scale" of sale and leaseback transactions associated with the sale of its intravascular ultrasound systems.